Characteristics of patients with major depressive disorder eligible for and prescribed esketamine, treatment outcomes and physician experiences: a physician and patient survey in the United States.
Current medical research and opinion February 1, 2025 Manish Jha, Amanda Teeple, Jason Shepherd et al.
Among 914 patients with treatment-resistant depression (TRD) or major depression with suicidal ideation (MDSI), moderate-to-very severe depression affected 36.5% of those with TRD and 48.3% of those with MDSI. Mean work impairment was 26% and overall impairment 34.7%. Most patients reported no-to-mild impairment in basic needs, social functioning, work, quality of life, and general health. Physicians underestimated the daily-life impact and unmet treatment need. Among 94 patients prescribed esketamine, improvements in clinical global impression occurred in 64.6-77.8% and in activities of daily living in 34-67%, indicating favorable outcomes.